Archives

  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-11
  • 2018-10
  • 2018-07
  • EZ Cap™ mCherry mRNA (5mCTP, ψUTP): Stable Cap 1 Red Fluo...

    2025-11-12

    EZ Cap™ mCherry mRNA (5mCTP, ψUTP): Stable Cap 1 Red Fluorescent Reporter

    Executive Summary: EZ Cap™ mCherry mRNA (5mCTP, ψUTP) is a synthetic messenger RNA encoding the monomeric red fluorescent protein mCherry, derived from Discosoma DsRed. The transcript is 996 nucleotides, supplied at ~1 mg/mL in 1 mM sodium citrate buffer (pH 6.4), and contains a Cap 1 structure added enzymatically to mimic mammalian mRNA capping. It includes 5-methylcytidine triphosphate (5mCTP) and pseudouridine triphosphate (ψUTP) modifications to reduce innate immune activation and enhance stability. The poly(A) tail further boosts translational efficiency. This reagent enables high-fidelity fluorescent protein expression for cellular imaging and molecular tracking (APExBIO product page; Guri-Lamce et al. 2024).

    Biological Rationale

    Fluorescent reporter genes such as mCherry facilitate direct visualization of cellular localization, trafficking, and expression dynamics. mCherry is a monomeric variant engineered from the tetrameric Discosoma red fluorescent protein (DsRed) (APExBIO). The mCherry open reading frame encodes a protein of 236 amino acids with an excitation maximum at 587 nm and emission at 610 nm, producing bright red fluorescence (mCherry mRNA with Cap 1 Structure: Protocols). Synthetic mRNAs, when capped with Cap 1, closely mimic native mammalian transcripts, supporting efficient translation and proper recognition by the cellular machinery. Modifications such as 5mCTP and ψUTP are critical in minimizing unwanted immune responses caused by exogenous RNA, a challenge in both cell and animal models (Guri-Lamce et al. 2024).

    Mechanism of Action of EZ Cap™ mCherry mRNA (5mCTP, ψUTP)

    EZ Cap™ mCherry mRNA (5mCTP, ψUTP) operates as a translation-ready, synthetic messenger RNA. The Cap 1 structure, introduced enzymatically using Vaccinia virus Capping Enzyme, GTP, SAM, and 2'-O-Methyltransferase, enables efficient ribosome recruitment and prevents rapid degradation (Redefining mRNA Reporter Systems). The inclusion of 5-methylcytidine and pseudouridine bases disrupts recognition by pattern recognition receptors (PRRs) such as Toll-like receptors and RIG-I, leading to suppression of innate immune activation. A poly(A) tail further stabilizes the mRNA and enhances translation initiation (EZ Cap™ mCherry mRNA: Cap 1 Reporter Gene). Upon delivery—often via lipid nanoparticles or electroporation—the mRNA is translated by host ribosomes, resulting in cytoplasmic accumulation of the mCherry protein, which emits characteristic red fluorescence under appropriate excitation (587 nm).

    Evidence & Benchmarks

    Applications, Limits & Misconceptions

    EZ Cap™ mCherry mRNA (5mCTP, ψUTP) is primarily used as a reporter gene in molecular and cell biology research. It enables precise fluorescent labeling for real-time imaging, cell tracking, transfection optimization, and molecular marker studies. The immune-evasive, stable design supports applications in challenging primary cells and in vivo models. The product’s robust translational performance is particularly advantageous in workflows requiring high signal-to-noise ratios and minimal background activation (Redefining mRNA Reporter Systems—this article expands on mechanistic and translational details not covered in that review).

    Common Pitfalls or Misconceptions

    • This mRNA construct does not integrate into the host genome; it is transiently expressed.
    • It is not suitable for applications requiring blue, green, or far-red fluorescence (mCherry emission is 610 nm).
    • Direct injection or electroporation without optimized delivery vehicles (e.g., LNPs) can lead to rapid degradation and poor signal.
    • Immune suppression by 5mCTP and ψUTP is significant but not absolute; some cell types may still mount a response under stress.
    • Storage above -40°C or repeated freeze-thaw cycles may degrade mRNA quality and reduce performance.

    Workflow Integration & Parameters

    EZ Cap™ mCherry mRNA (5mCTP, ψUTP) is supplied at ~1 mg/mL in 1 mM sodium citrate buffer, pH 6.4. For cell transfection, typical working concentrations range from 0.1–2 μg per well (24-well plate), depending on cell type and delivery system. For in vivo use, optimization of LNP formulation, dosing (e.g., μg per mouse), and injection route (intravenous, intramuscular, etc.) are required (Guri-Lamce et al. 2024). Store the product at or below -40°C to prevent degradation. Thaw on ice and avoid repeated freeze-thaw. For troubleshooting and advanced workflow guidance, see mCherry mRNA with Cap 1 Structure: Protocols & Advanced Applications—this article clarifies parameters for immune suppression and signal optimization not detailed in the protocol article.

    Conclusion & Outlook

    EZ Cap™ mCherry mRNA (5mCTP, ψUTP) from APExBIO offers a high-performance, immune-evasive reporter system for molecular and cell biology research. Its Cap 1 capping and nucleotide modifications set a new standard for stability and translational output in both in vitro and in vivo applications. Ongoing advances in LNP delivery and synthetic mRNA chemistry will likely extend the utility of such reagents, with potential for further immune modulation and multiplexed imaging. For detailed specifications, refer to the product page (R1017 kit).